The new technology is used to isolate and collect patient’s mononuclear cells which are then implanted to a bioengineered grafts in patients with congenital heart defects to replace damaged or missing blood vessels.
Pall Medical president Byron Selman said since the system is pre-connected and completely closed, the entire process can be started and completed right next to the operating table, eliminating the need for a clean room and limiting the possibility of contamination.
